Irvine, United States
CenSyn, Inc. is a promising pre-FDA stage medical device startup that aims to revolutionize the field of clinical neurology with its handheld EEG monitoring device. The company's slogan, "Instant insight, one mind at a time," encapsulates its commitment to providing accessible brain health data to clinicians. Founded in 2019 and headquartered in the United States, CenSyn is focused on addressing the unmet needs in neurological care, particularly in accelerating screening for conditions such as Alzheimer's, Traumatic Brain Injury, and Epilepsy.
The core value proposition of CenSyn lies in the potential to facilitate early screening of neurological conditions, thereby contributing to improved patient outcomes and reduced healthcare costs. The company has already developed a functional prototype capable of acquiring and displaying EEG signals in less than a minute, complemented by software integrations for remote brain/tele-neurology monitoring.
Currently, CenSyn is in the midst of conducting a 50 patient validation study to assess the efficacy of its device. Notably, the company has also embarked on the creation of its proprietary EEG database, positioning itself for future opportunities in Artificial Intelligence value creation.
Receiving a Grant investment at 16 November 2023 from the National Science Foundation, CenSyn has already garnered recognition and support from prominent entities. With its innovative approach and strategic initiatives, CenSyn presents an intriguing investment opportunity in the Health Care and Sports industries. As the company continues to progress on its journey, it invites stakeholders to connect and join in shaping the future of neurological care.
